Evidence (sorafenib): A phase III, randomized, double-blind, placebo-controlled study (DECISION [NCT00984282]) evaluated sorafenib in patients with progressive, iodine-refractory, differentiated thyroid cancer.[21] This trial included 417 patients with locally advanced or metastatic RAI-refractory thyroid cancer (papillary, follicular [including Hrthle cell], and poorly differentiated tumors) whose disease had progressed within the past 14 months
It keeps your immune system strong, your muscle mass and metabolism steady, supports bone health, and helps maintain your hair, nails, and skin
Reddys) : 88 120 $/mois selon la pharmacie disponibles depuis mai 2026 [17][18][19] Ozempic de marque (Novo Nordisk) : 250 310 $/mois sans couverture, ou align sur les gnriques avec la carte Extra Savings [18] Pour rfrence historique : avant larrive des gnriques, lOzempic de marque cotait 200270 $/mois selon la dose prescrite (janvier 2026) [1][2]
Hematologic Cancers Among Patients with Type 2 Diabetes Prescribed GLP-1 Receptor Agonists
